0 CHECKOUT

PRODUCT FILTERS

REGION

50
2
2
2

COUNTRY

2

PRICE

0
5
6
54

PUBLISHED

0
1
2
54

PRODUCT TYPE

54

Leukemia

On average over 40,000 are diagnosed with leukemia each year in the United States. It is also one of the most common cancers in children. Large differences in therapeutic outcomes exist among patient groups such as children and old age sufferers, and according to the form of a disease that has many variants such as Acute (AML) and Chronic (CML) Myelocytic Leukemia, Acute (ALL) and Chronic (CLL) Lymphocytic Leukemia, and Hairy Cell Leukemia (HCL). These variations have led to unmet needs among specific patient groups. The selection of expert and insightful reports in this section enable you explore these market opportunities by providing key industry data such as drug development strategies, international market trends and forecasts and profiles of major players like Novartis, Pfizer and Bristol-Myers Squibb. Show Less Read more

54 Products

Global Acute Myeloid Leukemia Therapeutics Market 2015-2019

About Acute Myeloid Leukemia Acute myeloid leukemia, also known as acute myelogenous leukemia, is a hematopoietic disorder that starts either in hematopoietic stem cells or lineage-specific progenitor...

Published:  December 2014
Price:  From

Leukemia Drug Pipeline Update 2015

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today 404 companies plus partners developing 533 leukemia drugs in 864 developmental...

Published:  June 2015
Price:  From
Leukemia Drug Pipeline Update 2015 Leukemia Drug Pipeline Update 2015 - Product Thumbnail Image

Analytical Tool - Leukemia

"Analytical Tool - Leukemia" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in leukemia R&D and business development. It is at the same time a map of...

Published:  March 2014
Price: 

Triple Analysis: Breast Cancer, Leukemia and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a...

Published:  June 2013
Price:  From

Triple Analysis: Colorectal Cancer, Leukemia and Melanoma

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in...

Published:  June 2013
Price:  From

Triple Analysis: Leukemia, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

Published:  June 2013
Price:  From

Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

Published:  June 2013
Price:  From

Triple Analysis: Leukemia, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

Published:  June 2013
Price:  From

Triple Analysis: Leukemia, Melanoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according...

Published:  June 2013
Price:  From

Triple Analysis: Leukemia, Melanoma and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

Published:  June 2013
Price:  From

Triple Analysis: Leukemia, Melanoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

Published:  June 2013
Price:  From

Triple Analysis: Leukemia, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

Published:  January 2013
Price:  From

Triple Analysis: Breast Cancer, Leukemia and Antibodies

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

Published:  November 2012
Price:  From

Triple Analysis: Colorectal Cancer, Leukemia and Antibodies

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

Published:  November 2012
Price:  From

Triple Analysis: Leukemia, Lung Cancer and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

Published:  November 2012
Price:  From

Triple Analysis: Leukemia, Lymphoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

Published:  November 2012
Price:  From

Triple Analysis: Leukemia, Pancreatic Cancer and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

Published:  November 2012
Price:  From

Triple Analysis: Leukemia, Prostate Cancer and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Prostate Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

Published:  November 2012
Price:  From

Triple Analysis: Leukemia, Apoptosis and Antibodies

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies)....

Published:  November 2012
Price:  From

Triple Analysis: Leukemia, Angiogenesis and Antibodies

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies)....

Published:  November 2012
Price:  From
Loading Indicator

Our Clients